Fulphila, which secured approval to reduce the duration of febrile neutropenia in patients treated with chemotherapy in certain types of cancer, has been co-developed by Mylan and Biocon. It is
Lynparza is a poly ADP-ribose polymerase (PARP) inhibitor co-developed by AstraZeneca with Merck. Abiraterone is the standard-of-care treatment in mCRPC. The combination of Lynparza and abiraterone was evaluated
The interim data from the phase 2 KEYNOTE-427 study showed an ORR of 38.2% in patients who received Keytruda monotherapy as first-line therapy. It is the primary endpoint of
The double-blind, placebo-controlled phase 2 study included 125 patients over the age of 18 and was undertaken across nearly 25 clinical sites in the US. Patients were randomized
The approval is for the drug to be taken orally twice daily (BID) in 10mg dosage for at least eight weeks, followed by 5mg BID or 10mg BID
Larotrectinib is an oral and highly selective investigational tropomyosin receptor kinase (TRK) inhibitor, which is currently under clinical development to treat patients with cancers that harbor a NTRK
The late-stage trial, dubbed IMpower130, assessed the efficacy and safety of Tecentriq in combination with carboplatin and nab-paclitaxel versus chemotherapy (carboplatin and nab-paclitaxel) alone for chemotherapy-naïve patients with stage IV non-squamous
The company decided to not to pursue the re-examination procedure, which the firm initially requested for the MAA of masitinib in the treatment of ALS. The firm has determined that
Top line results from the study announced last month revealed the treatment missed its primary endpoint. Howevr, additional data analysis showed that in the European cohort, Lupuzor had a statistically significant 71.1% response rate against
The phase I MMY2036 study of daratumumab plus JNJ-63723283, an anti PD-1 antibody in patients with multiple myeloma, will also be terminated. The Data Monitoring Committee (DMC) has
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.